KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash & Equivalents (2016 - 2025)

Gilead Sciences' Cash & Equivalents history spans 17 years, with the latest figure at $7.6 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 24.29% year-over-year to $7.6 billion; the TTM value through Dec 2025 reached $7.6 billion, down 24.29%, while the annual FY2025 figure was $7.6 billion, 24.29% down from the prior year.
  • Cash & Equivalents reached $7.6 billion in Q4 2025 per GILD's latest filing, up from $7.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $10.0 billion in Q4 2024 to a low of $2.8 billion in Q2 2024.
  • Average Cash & Equivalents over 5 years is $5.5 billion, with a median of $5.1 billion recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 66.15% in 2021, then soared 85.57% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $5.3 billion in 2021, then increased by 1.39% to $5.4 billion in 2022, then increased by 12.44% to $6.1 billion in 2023, then surged by 64.19% to $10.0 billion in 2024, then fell by 24.29% to $7.6 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Cash & Equivalents are $7.6 billion (Q4 2025), $7.3 billion (Q3 2025), and $5.1 billion (Q2 2025).